APLLTDPharmaceuticals
Alembic Pharmaceuticals Ltd — Profit & Loss Statement
₹663.25
-2.97%
Alembic Pharmaceuticals Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Interest Income | 5.96 Cr | 2.09 Cr | 0.33 Cr | 1.73 Cr | — |
| Tax Effect Of Unusual Items | 2.26 Cr | 0.13 Cr | -0.32 Cr | -0.23 Cr | — |
| Tax Rate For Calcs | 0.18 | 0.03 | 0.04 | 0.17 | — |
| Normalized EBITDA | 1.05K Cr | 955.48 Cr | 689.11 Cr | 931.26 Cr | — |
| Total Unusual Items | 12.79 Cr | 5.21 Cr | -8.92 Cr | -1.36 Cr | — |
| Total Unusual Items Excluding Goodwill | 12.79 Cr | 5.21 Cr | -8.92 Cr | -1.36 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 583.42 Cr | 615.82 Cr | 341.99 Cr | 520.94 Cr | — |
| Reconciled Depreciation | 278.58 Cr | 272.67 Cr | 275.43 Cr | 286.78 Cr | — |
| Reconciled Cost Of Revenue | 2.14K Cr | 2.00K Cr | 2.02K Cr | 1.72K Cr | — |
| EBITDA | 1.06K Cr | 960.69 Cr | 680.19 Cr | 929.90 Cr | — |
| EBIT | 785.95 Cr | 688.02 Cr | 404.76 Cr | 643.12 Cr | — |
| Net Interest Income | -72.81 Cr | -54.10 Cr | -49.84 Cr | -16.00 Cr | — |
| Interest Expense | 78.77 Cr | 56.19 Cr | 50.17 Cr | 17.73 Cr | — |
| Normalized Income | 572.89 Cr | 610.74 Cr | 350.59 Cr | 522.07 Cr | — |
| Net Income From Continuing And Discontinued Operation | 583.42 Cr | 615.82 Cr | 341.99 Cr | 520.94 Cr | — |
| Total Expenses | 5.80K Cr | 5.45K Cr | 5.06K Cr | 4.64K Cr | — |
| Diluted Average Shares | 19.66 Cr | 19.66 Cr | 19.66 Cr | 19.66 Cr | — |
| Basic Average Shares | 19.66 Cr | 19.66 Cr | 19.66 Cr | 19.66 Cr | — |
| Diluted EPS | 29.68 | 31.33 | 17.40 | 26.50 | — |
| Basic EPS | 29.68 | 31.33 | 17.40 | 26.50 | — |
| Diluted NI Availto Com Stockholders | 583.42 Cr | 615.82 Cr | 341.99 Cr | 520.94 Cr | — |
| Net Income Common Stockholders | 583.42 Cr | 615.82 Cr | 341.99 Cr | 520.94 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 583.42 Cr | 615.82 Cr | 341.99 Cr | 520.94 Cr | — |
| Minority Interests | 1.41 Cr | 0.00 | — | 24.75 Cr | 31.61 Cr |
| Net Income Including Noncontrolling Interests | 582.01 Cr | 615.82 Cr | 341.99 Cr | 520.94 Cr | — |
| Net Income Continuous Operations | 582.01 Cr | 615.83 Cr | 341.98 Cr | 520.93 Cr | — |
| Tax Provision | 125.17 Cr | 16.00 Cr | 12.61 Cr | 104.46 Cr | — |
| Pretax Income | 707.18 Cr | 631.83 Cr | 354.59 Cr | 625.39 Cr | — |
| Other Non Operating Income Expenses | 7.89 Cr | 0.45 Cr | 0.27 Cr | 0.13 Cr | — |
| Special Income Charges | 11.32 Cr | 0.82 Cr | -9.67 Cr | -4.23 Cr | — |
| Other Special Charges | -16.63 Cr | -3.68 Cr | 3.32 Cr | -1.01 Cr | — |
| Write Off | 5.31 Cr | 2.86 Cr | 6.35 Cr | 5.24 Cr | — |
| Net Non Operating Interest Income Expense | -72.81 Cr | -54.10 Cr | -49.84 Cr | -16.00 Cr | — |
| Interest Expense Non Operating | 78.77 Cr | 56.19 Cr | 50.17 Cr | 17.73 Cr | — |
| Interest Income Non Operating | 5.96 Cr | 2.09 Cr | 0.33 Cr | 1.73 Cr | — |
| Operating Income | 735.04 Cr | 663.54 Cr | 444.08 Cr | 592.98 Cr | — |
| Operating Expense | 3.67K Cr | 3.45K Cr | 3.03K Cr | 2.92K Cr | — |
| Other Operating Expenses | 604.29 Cr | 575.59 Cr | 518.40 Cr | 417.88 Cr | — |
| Depreciation And Amortization In Income Statement | 278.58 Cr | 272.67 Cr | 275.43 Cr | 286.78 Cr | — |
| Depreciation Income Statement | 278.58 Cr | 272.67 Cr | 275.43 Cr | 286.78 Cr | — |
| Research And Development | 9.60 Cr | 20.98 Cr | 29.07 Cr | 50.59 Cr | — |
| Selling General And Administration | 1.35K Cr | 1.25K Cr | 1.19K Cr | 1.10K Cr | — |
| Selling And Marketing Expense | 1.06K Cr | 996.88 Cr | 952.30 Cr | 890.38 Cr | — |
| General And Administrative Expense | 280.46 Cr | 251.97 Cr | 241.05 Cr | 210.98 Cr | — |
| Gross Profit | 4.40K Cr | 4.11K Cr | 3.48K Cr | 3.51K Cr | — |
| Cost Of Revenue | 2.14K Cr | 2.00K Cr | 2.02K Cr | 1.72K Cr | — |
| Total Revenue | 6.54K Cr | 6.11K Cr | 5.50K Cr | 5.23K Cr | — |
| Operating Revenue | 6.54K Cr | 6.11K Cr | 5.50K Cr | 5.23K Cr | — |
| Rent Expense Supplemental | — | — | — | — | 1.62 Cr |
| Rent And Landing Fees | — | — | — | — | 1.62 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Alembic Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.